Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Curatis increases revenue in first half by 51% and reduces loss
Curatis raised net revenue in H1 2026 by 51% to CHF 7.9 million, with product sales of CHF 7.4 million and service sales of CHF 0.6 million. The deficit shrank to CHF 0.4 million after −CHF 1.2 million the previous year, and cash and cash equivalents rose to CHF 3.6 million thanks to a convertible instrument placed in May for CHF 3 million. For 2026 the biotech company confirms the revenue guidance raised in June of around CHF 15 million and aims for a breakeven result. For its key project Corticorelin (C-PTBE-01), a meeting with the FDA to define the Phase‑III study design is planned for Q1 2027. » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 8,6 M | - |
| Beneficio bruto | 268,67 mil | - |
| Beneficio neto | -440,92 mil | - |
| EBITDA | -226,42 mil | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 87,49 M € |
Número de acciones | 5,31 M |
Máximo/mínimo de 52 semanas | 30,12 € - 11,93 € |
| Dividendos | No |
Beta | -0,81 |
Ratio P/E | -119,98 |
Ratio PEG | 4,04 |
Ratio P/B | 1,62 |
Ratio P/S | 6,00 |
Perfil de la empresa
| Nombre | Curatis Holding AG |
| CEO | Roland Rutschmann |
| Empleados | 9 |